Gout | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 0810 governing gout treatment coverage, effective March 28, 2026. Here's what billing teams need to do.

Aetna updated its gout coverage policy under CPB 0810 — the clinical policy bulletin that governs medical necessity criteria, covered treatments, and exclusions for gout management across Aetna plans. This policy covers the full spectrum of gout care, from urate-lowering therapies and anti-inflammatory treatments to injectable biologics and advanced diagnostics. The full policy document is available at the PayerPolicy source link. The specific details of what changed in this revision are not included in the available policy data, which means your billing team needs to review the updated CPB 0810 directly before the effective date of March 28, 2026.

Aetna Gout Coverage Criteria and Medical Necessity Requirements 2026

The Aetna gout coverage policy under CPB 0810 governs what gout-related treatments, diagnostics, and medications Aetna considers medically necessary. Gout policies at major payers typically address three broad categories: diagnostic workup, acute flare management, and long-term urate-lowering therapy (ULT).

For billing teams, the medical necessity question usually turns on two things: the severity of disease and the failure of first-line therapies. Aetna, like most payers, requires documentation of hyperuricemia confirmed by serum uric acid levels, clinical diagnosis of gout, and often a documented trial of standard agents like allopurinol before it will approve advanced treatments.

Prior authorization is typically required for advanced urate-lowering agents, biologic therapies like pegloticase (Krystexxa), and certain infusion-based treatments. If your practice manages patients with refractory or tophaceous gout, prior auth requirements in this policy revision deserve close attention. If you're not sure how prior authorization requirements apply to your current patient mix, loop in your billing consultant or compliance officer before the March 28, 2026 effective date.

The Aetna gout billing guidelines under CPB 0810 also interact with pharmacy benefit management. Many gout drugs — febuxostat, colchicine, pegloticase — move between the medical and pharmacy benefit depending on how they're administered. Infused biologics billed on the medical benefit have different prior auth and reimbursement pathways than orally administered drugs under the pharmacy benefit. Your team needs to know which bucket each treatment falls into.

Because the specific revisions in this March 28, 2026 update are not detailed in the available policy data, the analysis below reflects standard CPB 0810 structure and known Aetna gout coverage policy requirements. Verify each criterion against the live policy document before submitting claims.

Aetna Gout Treatment Exclusions and Non-Covered Indications

Aetna's coverage policy for gout has historically excluded several indications as experimental, investigational, or not medically necessary. Billing teams should know these categories well — claim denial risk is highest when documentation doesn't clearly distinguish a covered indication from an excluded one.

Treatments typically not covered under gout clinical policy bulletins like CPB 0810 include:

The real issue here is that gout treatment has a clear clinical ladder — diagnostics, first-line ULT, advanced ULT, infusion therapy — and Aetna's coverage policy requires documentation that your patient is on the right rung before it will approve the next one. If your charts don't tell that story clearly, expect a claim denial.

Experimental or unproven indications in gout management typically include off-label uses of IL-1 inhibitors (like anakinra or canakinumab) for acute flare management outside of approved protocols. These are high-cost items with significant reimbursement exposure. If your rheumatology team uses these agents, verify their status in the updated CPB 0810 directly.

Coverage Indications at a Glance

The policy data provided does not include indication-level coverage details from the revised CPB 0810. The table below reflects standard Aetna gout coverage policy structure. Verify each row against the live policy before the effective date of March 28, 2026.

Aetna Gout Billing Guidelines and Action Items 2026

Here's what your team needs to do before March 28, 2026.

CPT, HCPCS, and ICD-10 Codes for Gout Under CPB 0810

The updated CPB 0810 policy data provided to PayerPolicy does not include a specific list of CPT, HCPCS, or ICD-10 codes. The policy does not list specific codes in the data available at this time.

This is not unusual for Aetna clinical policy bulletins — CPB documents often govern medical necessity criteria and coverage determinations without enumerating every applicable billing code. The codes your billing team uses for gout services are determined by the specific procedure, drug, or service rendered, not by the CPB itself.

For reference, gout billing commonly involves codes across several categories. Pull the live CPB 0810 document and cross-reference with your current charge capture to confirm which are governed by this specific policy.

Common code categories in gout billing include joint aspiration and injection codes, infusion administration codes for pegloticase, laboratory codes for uric acid testing and synovial fluid analysis, and ICD-10-CM codes in the M10 range for gout diagnoses. Confirm every code against the updated policy before submitting claims on or after March 28, 2026.

If you need the specific current codes used in your gout workflows validated against CPB 0810, engage your billing consultant or check the full policy document directly at the Aetna source.